Mineralys Therapeutics: UBS cuts target price to $19 from $29
MLYS•UBS cut its target price for Mineralys Therapeutics to $19 from $29.
Related News
JFrog jumps as Q3 profit, revenue beat estimates
FROG•
Tapestry, Inc.: UBS raises target price to $203 from $200
TPR•
Networking firm Extreme Networks explores sale, sources say
EXTR•
Perimeter Solutions, Inc.: UBS raises target price to $40 from $38
PRM•
Cloudflare: UBS cuts target price to $300 from $350
NET•